Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19
By HospiMedica International staff writers Posted on 22 May 2020 |
Image: Scientists Use Virtual Reality to Refine New AI-Generated Drugs for COVID-19 (Photo courtesy of Nanome, Inc.)
A team of researchers have used artificial intelligence (AI) to generate 10 potential small molecule inhibitors targeting the SARS-CoV-2 main protease.
The study conducted by virtual reality (VR) startup Nanome, Inc. (San Diego, CA, USA) in collaboration with artificial intelligence company Insilico Medicine (Hong Kong) could reveal as-of-yet-undiscovered methods for attacking the virus that have eluded scientists working with existing drug candidates.
Several potential therapeutics aimed at containing the spread of SARS-CoV-2 have targeted the S, or spike, protein, a surface protein that plays a vital role in viral entry into host cells. However, according to the researchers, two-thirds of the SARS-CoV-2 genome comprises non-structural proteins, such as the viral protease (the protein necessary for viral replication), which should not be overlooked as potential therapeutic targets. However, since the beginning of the COVID-19 outbreak, only a few studies on novel SARS-CoV-2 protease inhibitors have been published.
To enable scientists to exploit the whole drug-like chemical space, the researchers have used recent advances in deep learning and AI to develop a new type of computational method for drug discovery termed as "AI imagination". Insilico's proprietary AI imagination platform has already been successfully applied to design small molecule drugs for a wide range of human diseases, such as cancer, fibrosis, and immunological diseases. In their study, the researchers used a protein structure to generate a number of novel, non-covalent drug candidates. The generation was followed by the selection of 10 representative examples and medicinal chemistry analysis in VR, provided by Nanome. The researchers hope their compounds will be synthesized and tested in vitro and in vivo in the future.
Related Links:
Nanome, Inc.
Insilico Medicine
The study conducted by virtual reality (VR) startup Nanome, Inc. (San Diego, CA, USA) in collaboration with artificial intelligence company Insilico Medicine (Hong Kong) could reveal as-of-yet-undiscovered methods for attacking the virus that have eluded scientists working with existing drug candidates.
Several potential therapeutics aimed at containing the spread of SARS-CoV-2 have targeted the S, or spike, protein, a surface protein that plays a vital role in viral entry into host cells. However, according to the researchers, two-thirds of the SARS-CoV-2 genome comprises non-structural proteins, such as the viral protease (the protein necessary for viral replication), which should not be overlooked as potential therapeutic targets. However, since the beginning of the COVID-19 outbreak, only a few studies on novel SARS-CoV-2 protease inhibitors have been published.
To enable scientists to exploit the whole drug-like chemical space, the researchers have used recent advances in deep learning and AI to develop a new type of computational method for drug discovery termed as "AI imagination". Insilico's proprietary AI imagination platform has already been successfully applied to design small molecule drugs for a wide range of human diseases, such as cancer, fibrosis, and immunological diseases. In their study, the researchers used a protein structure to generate a number of novel, non-covalent drug candidates. The generation was followed by the selection of 10 representative examples and medicinal chemistry analysis in VR, provided by Nanome. The researchers hope their compounds will be synthesized and tested in vitro and in vivo in the future.
Related Links:
Nanome, Inc.
Insilico Medicine
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans